GO:0044389 ubiquitin-like protein ligase binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0044389 (ubiquitin-like protein ligase binding) is a molecular function describing the selective binding of a protein to a ubiquitin-like protein ligase, such as an E3 ubiquitin ligase.
• This binding event is the physical foundation of substrate recognition in ubiquitin and ubiquitin-like conjugation cascades, determining which proteins are modified and ultimately degraded or re-localized.
• The term covers binding to E3 enzymes that transfer ubiquitin and ubiquitin-like modifiers (SUMO, NEDD8, ISG15, etc.) to substrates, and it is mechanistically distinct from being a ligase itself.
• Dysregulated ligase binding underlies cancer, neurodegeneration, and inflammatory disease, making these interactions high-value drug targets such as PROTACs.
• Key experimental approaches include knockout/knock-in cell models, affinity proteomics, and CRISPR library screening to map ligase-substrate networks.
• EDITGENE provides ready-to-use knockout, point-mutation, knock-in, overexpression cell models and CRISPR screening/bioinformatics services to study GO:0044389-dependent pathways.
Description
GO:0044389, ubiquitin-like protein ligase binding, is a Gene Ontology molecular function that describes the ability of a protein to selectively bind a ubiquitin-like protein ligase, including E3 ubiquitin ligases and related enzymes that conjugate ubiquitin or ubiquitin-like modifiers to target proteins. This binding function is central to the ubiquitin-proteasome system and to ubiquitin-like modification cascades, because it determines substrate recruitment and the specificity of downstream modification. In practical terms, any protein annotated with GO:0044389 acts as a physical interaction partner for a ligase, often as a substrate receptor, adaptor, or regulatory subunit. The importance of this term for researchers lies in its direct link to protein stability, signaling, and disease. For example, the von Hippel-Lindau (VHL) E3 ligase binds hydroxylated HIF-alpha, leading to its ubiquitination and destruction under normoxic conditions, a classic illustration of ligase binding controlling a key oxygen-sensing pathway. Similarly, engineered chimeric molecules such as PROTACs exploit ligase binding to redirect the Skp1-Cullin-F box complex to degrade selected proteins, demonstrating the therapeutic tractability of this function. Because ligase binding is a molecular recognition event, it is studied with a combination of genetic, biochemical, and proteomic methods. Knockout and knock-in cell models, affinity purification, and CRISPR screening are routinely used to identify and validate ligase-substrate interactions. This article summarizes the definition, mechanism, key genes, disease relevance, and research methods for GO:0044389, with a focus on how CRISPR-based models can be used to interrogate this function.
ubiquitin-like protein ligase binding At A Glance
| GO ID | GO:0044389 |
|---|---|
| GO term | ubiquitin-like protein ligase binding |
| Ontology | molecular_function |
| Synonym | E3 protein ligase binding; small conjugating protein ligase binding |
| Major function | Selective binding to a ubiquitin-like protein ligase, enabling substrate recognition and modification in ubiquitin and ubiquitin-like conjugation pathways. |
| Example interaction | VHL E3 ligase binding to hydroxylated HIF-alpha, leading to its ubiquitination and degradation. |
| Therapeutic relevance | Ligase-binding interfaces are exploited by PROTACs and other degrader molecules to redirect ubiquitination to chosen targets. |
| Related processes | Ubiquitin-mediated proteolysis, SUMOylation, neddylation, and other ubiquitin-like modification cascades. |
What Is GO:0044389?
In our own words, GO:0044389 (ubiquitin-like protein ligase binding) is the molecular function of selectively and non-covalently interacting with a ubiquitin-like protein ligase, such as an E3 ubiquitin-protein ligase. The term is used when a protein binds a ligase enzyme that transfers ubiquitin or a ubiquitin-like modifier to a substrate. It does not describe the catalytic activity of the ligase itself, but rather the binding event that positions a protein as a substrate, adaptor, or regulator within a ubiquitin-like conjugation pathway.
Why Is ubiquitin-like protein ligase binding Important in Cell Biology?
GO:0044389 is important because it defines the molecular recognition step that gives ubiquitin and ubiquitin-like modification systems their specificity. Without selective ligase binding, cells could not target individual proteins for degradation, trafficking, or signaling changes, and processes such as oxygen sensing, inflammasome activation, and purinosome assembly would be dysregulated. Because many diseases involve abnormal protein stability or ligase activity, understanding and manipulating ligase binding is a major goal in drug discovery and functional genomics.
• Controls substrate selection in ubiquitin-proteasome-mediated degradation, a central pathway for protein quality control.
• Enables oxygen sensing through VHL binding to hydroxylated HIF-alpha, linking ligase binding to hypoxia signaling.
• Supports inflammatory signaling, for example TRIM28 binding and SUMOylation of NLRP3 during inflammasome activation.
• Contributes to metabolic compartmentalization, as seen in PAICS ubiquitination and UBAP2 recruitment for purinosome assembly.
• Provides the mechanistic basis for PROTAC-induced degradation of disease-causing proteins.
• Is relevant to autophagy and age-related macular degeneration through ubiquitin-like conjugation and cargo recognition.
• Offers a target space for small molecules that disrupt or enhance ligase-substrate interactions.
• Can be systematically mapped using CRISPR knockout and knock-in screens combined with proteomics.
Molecular Mechanism of ubiquitin-like protein ligase binding
Substrate recognition by the ligase
In simple terms: The ligase must first grab the right protein before it can tag it.
In ubiquitin-like protein ligase binding, the ligase or its substrate receptor recognizes a specific degron or interaction motif on the target protein. This binding event is non-covalent and determines whether the target will subsequently be modified with ubiquitin or a ubiquitin-like modifier. For example, VHL binds HIF-alpha only after proline hydroxylation, illustrating how a post-translational modification can create a ligase-binding interface.
Assembly of the conjugation complex
In simple terms: Binding brings together the machinery that attaches ubiquitin-like tags.
Once the ligase binds its substrate, it assembles with E2 conjugating enzymes and, in some cases, adaptor proteins to form a functional conjugation complex. The binding function of GO:0044389 is often mediated by domains such as RING, HECT, or substrate-receptor domains that physically contact the ligase. This step ensures that the ubiquitin-like modifier is transferred to the correct lysine residue on the substrate.
Modifier transfer and substrate fate
In simple terms: After binding, the tag is attached and the protein's fate changes.
Following ligase binding, ubiquitin or a ubiquitin-like modifier is covalently attached to the substrate. The consequence can be proteasomal degradation, altered localization, or changes in activity, depending on the type and topology of the modification. In the case of PAICS, ubiquitination recruits UBAP2 and triggers phase separation for purinosome assembly, showing that ligase binding can drive non-degradative outcomes.
Regulation by post-translational modifications
In simple terms: Chemical marks on the ligase or substrate can switch binding on or off.
Ligase binding is regulated by phosphorylation, hydroxylation, SUMOylation, and other modifications. For instance, TRIM28 SUMOylates and stabilizes NLRP3, linking a ubiquitin-like modification to inflammasome activation. Deubiquitinases can also reverse these events and thereby modulate the lifetime of ligase-substrate complexes.
Cofactors and interaction specificity
In simple terms: Helper molecules and domains decide which ligase binds which target.
Specificity of GO:0044389 is often conferred by accessory proteins, substrate receptors, and cofactors. The Skp1-Cullin-F box complex, for example, uses F-box proteins to recognize substrates, and PROTACs exploit this system by presenting a target-binding moiety linked to a ligase-binding moiety. Such modularity allows a limited number of ligases to regulate many substrates.
Key Genes Involved in GO:0044389 ubiquitin-like protein ligase binding
The following genes and proteins are representative examples of factors that bind ubiquitin-like protein ligases or act as ligases in pathways annotated with GO:0044389.
| Gene | Major Role | Research Relevance |
|---|---|---|
| VHL | Substrate receptor of a Cullin-RING E3 ligase that binds hydroxylated HIF-alpha | Model for oxygen sensing and ligase-substrate recognition |
| TRIM28 | SUMOylates and stabilizes NLRP3, acting as a ubiquitin-like ligase regulator | Inflammasome and innate immunity studies |
| NLRP3 | Inflammasome sensor whose stability is controlled by TRIM28-mediated SUMOylation | Inflammation and autoinflammatory disease models |
| PAICS | Purine biosynthetic enzyme that is ubiquitinated and recruits UBAP2 | Purinosome assembly and metabolic compartmentalization |
| UBAP2 | Ubiquitin-associated protein that binds ubiquitinated PAICS to promote phase separation | Study of ubiquitin-dependent condensate formation |
| DTX3L | Ubiquitin ligase that ubiquitinates single-stranded nucleic acids | DNA damage and innate immune signaling |
| Skp1 | Component of the SCF complex that binds F-box proteins and substrates | PROTAC and targeted degradation research |
| Cullin | Scaffold of Cullin-RING ligases that binds substrate receptors | Ligase complex assembly and drug discovery |
| F-box protein | Substrate receptor that binds targets for SCF-mediated ubiquitination | Specificity of ligase-substrate interactions |
| HIF1A | Transcription factor degraded after VHL binding and ubiquitination | Hypoxia and cancer metabolism |
| UBB | Ubiquitin precursor whose conjugation is central to ligase function | Core ubiquitin pathway studies |
| UBC | Ubiquitin-conjugating enzyme family member acting with ligases | Enzyme cascade reconstitution |
| SUMO1 | Ubiquitin-like modifier transferred by SUMO ligases | SUMOylation and protein stability |
| NEDD8 | Ubiquitin-like modifier that modifies Cullins and regulates ligase activity | Cullin-RING ligase regulation |
| ATG proteins | Autophagy-related proteins that interact with ubiquitin-like conjugation systems | Autophagy and macular degeneration research |
| Deubiquitinases | Enzymes that remove ubiquitin and modulate ligase-substrate complexes | Reversibility and specificity studies |
How Is ubiquitin-like protein ligase binding Regulated?
GO:0044389-dependent binding is regulated at multiple levels. Post-translational modifications such as hydroxylation, phosphorylation, and SUMOylation can create or destroy ligase-binding interfaces, as shown for HIF-alpha and NLRP3. Deubiquitinases counteract ligase activity and can edit ubiquitin chains to change binding outcomes. In addition, the availability of cofactors and adaptor proteins, such as F-box proteins in SCF complexes, determines which substrates are recognized. Autophagy-related ubiquitin-like conjugation systems add another layer of regulation by routing cargo to degradation pathways.
ubiquitin-like protein ligase binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| VHL | Von Hippel-Lindau disease and clear cell renal cell carcinoma | VHL knockout or point-mutation cell lines with HIF reporter assays |
| NLRP3 | Inflammasome-driven autoinflammatory syndromes | TRIM28 knockout or SUMOylation-site mutant macrophages |
| PAICS | Purine metabolism and purinosome-related metabolic stress | PAICS knockout with UBAP2 tagged knock-in for imaging |
| DTX3L | DNA damage response and immune signaling | DTX3L knockout cells treated with DNA-damaging agents |
| ATG-related genes | Age-related macular degeneration and autophagy dysfunction | Autophagy reporter cells with CRISPR knockout of ATG genes |
Cancer and hypoxia signaling
VHL binding to hydroxylated HIF-alpha is a paradigm for ligase-substrate recognition, and loss of this binding leads to HIF accumulation and tumor angiogenesis. PROTACs that redirect E3 ligases to oncoproteins demonstrate that manipulating GO:0044389 interactions can be therapeutically useful in cancer.
Inflammatory and autoinflammatory disease
TRIM28-mediated SUMOylation and stabilization of NLRP3 promotes inflammasome activation, linking ubiquitin-like ligase binding to inflammatory disease. Modulating this interaction could influence cytokine release and inflammation.
Metabolic and neurodegenerative disorders
Ubiquitin-dependent processes, including PAICS ubiquitination and purinosome assembly, connect ligase binding to metabolic regulation. Impaired ubiquitin-proteasome function is also implicated in protein aggregation diseases, and autophagy-related ubiquitin-like conjugation is relevant to age-related macular degeneration.
DNA damage and genome stability
DTX3L ubiquitinates single-stranded nucleic acids, indicating that ligase binding and ubiquitin-like modification can directly influence DNA repair and innate immune sensing. This expands the disease relevance of GO:0044389 beyond protein degradation.
From ubiquitin-like protein ligase binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate ligase-binding protein alter substrate stability? | CRISPR knockout cell line with western blot and cycloheximide chase |
| Does a specific phospho-site control ligase binding? | Point-mutation knock-in of the phospho-dead or phospho-mimetic residue |
| Can a ligase-substrate interaction be visualized in live cells? | Tagged knock-in of the substrate or ligase with fluorescent or proximity-labeling tags |
| Does overexpression of a ligase-binding protein drive pathway activation? | Doxycycline-inducible overexpression cell model |
| Which genes modify the ligase-binding phenotype? | Genome-wide CRISPR knockout or activation library screening |
| Does a disease-associated mutation affect ligase recruitment? | Patient-derived iPSCs or isogenic knock-in lines carrying the mutation |
How to Study the ubiquitin-like protein ligase binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Co-immunoprecipitation | Physical interaction between a ligase and candidate protein | Validation of GO:0044389 binding |
| Mass spectrometry | Protein complexes and modification sites | Mapping ligase interactomes and ubiquitination sites |
| CRISPR knockout screening | Genes required for a ligase-binding phenotype | Discovery of pathway components |
| Western blot with cycloheximide chase | Substrate stability over time | Testing whether ligase binding leads to degradation |
| Fluorescence microscopy | Subcellular localization and condensate formation | Studying purinosome assembly and phase separation |
| SUMOylation assays | Covalent attachment of SUMO to substrates | Analyzing TRIM28-NLRP3 regulation |
| Proximity labeling | Spatially restricted interactors of a ligase | Identifying transient ligase-substrate contacts |
| Reporter assays | Transcriptional or signaling output of a pathway | Measuring HIF or inflammasome activity |
Affinity proteomics and interactome mapping
Affinity purification coupled to mass spectrometry can identify proteins that bind ubiquitin-like ligases, directly mapping GO:0044389 interactions. Tagged ligases or substrate baits expressed in knockout background cells reduce false positives and help define the binding interface.
CRISPR screening for ligase-substrate networks
Genome-wide CRISPR knockout or activation screens can identify genes that regulate ligase binding and downstream substrate fate. Such screens are particularly useful for discovering adaptors and modifiers of E3 ligase complexes.
Proteomics of ubiquitin and ubiquitin-like modifications
DiGly enrichment and SUMO remnant profiling can quantify ubiquitination and SUMOylation changes after manipulating candidate ligase-binding proteins. These methods connect binding events to global modification landscapes.
Imaging and phase-separation assays
Fluorescence microscopy of tagged proteins, including knock-in reporters, can reveal whether ligase binding drives condensate formation, as shown for PAICS and UBAP2 in purinosome assembly. Live-cell imaging provides spatial and temporal resolution of binding events.
How CRISPR Can Be Used to Study GO:0044389 ubiquitin-like protein ligase binding
Knockout
CRISPR knockout of a ligase or substrate-receptor gene removes the binding function and allows researchers to test loss-of-function phenotypes. For example, VHL knockout stabilizes HIF-alpha and activates hypoxia reporters, providing a clean readout for GO:0044389-dependent degradation. Knockout models are also used to validate hits from CRISPR screens.
Point Mutation
Point-mutation knock-in can disrupt a single binding interface without deleting the entire protein. This is useful for testing whether a specific phospho-site or degron is required for ligase binding, as in HIF-alpha proline hydroxylation mutants that fail to bind VHL. Such models separate binding from other functions of the protein.
Knock-in
Tagged knock-in of a ligase or substrate with fluorescent, affinity, or proximity-labeling tags enables visualization and purification of endogenous complexes. Knock-in of UBAP2 or PAICS tags can reveal how ubiquitination recruits phase-separating proteins in living cells. Knock-in also preserves endogenous expression levels, avoiding overexpression artifacts.
Overexpression
Overexpression of a ligase-binding protein or a dominant-negative ligase can amplify or block pathway output. Inducible overexpression of TRIM28 or NLRP3 variants can test effects on inflammasome activation and SUMOylation. Overexpression is often combined with knockout backgrounds to isolate specific interactions.
How EDITGENE Supports ubiquitin-like protein ligase binding Research
Researchers studying ubiquitin-like protein ligase binding-related genes often need to determine whether a candidate gene is causally involved in substrate recognition, modification, or downstream disease phenotypes. EDITGENE provides validated CRISPR cell models and screening services that make these experiments reproducible and scalable.
Contact EDITGENE today to design your custom CRISPR model for ubiquitin-like protein ligase binding research.
Frequently Asked Questions About ubiquitin-like protein ligase binding
What is GO:0044389?
GO:0044389 is the Gene Ontology molecular function term for ubiquitin-like protein ligase binding, which describes selective binding to a ubiquitin-like protein ligase such as an E3 ubiquitin ligase.
What does ubiquitin-like protein ligase binding mean in simple terms?
It means a protein physically grabs a ligase enzyme that attaches ubiquitin or a similar tag to target proteins, helping decide which proteins get modified.
What genes are involved in ubiquitin-like protein ligase binding?
Examples include VHL, TRIM28, NLRP3, PAICS, UBAP2, DTX3L, and components of the SCF complex such as Skp1, Cullin, and F-box proteins.
How is ubiquitin-like protein ligase binding studied?
Common methods include co-immunoprecipitation, mass spectrometry, CRISPR knockout screens, western blotting, and fluorescence imaging of tagged proteins.
Why is GO:0044389 important in cancer?
Ligase binding controls the stability of proteins such as HIF-alpha, and disrupting these interactions can drive tumor growth; PROTACs exploit ligase binding to degrade oncoproteins.
What is the difference between a ligase and ligase binding?
A ligase catalyzes the attachment of ubiquitin or a ubiquitin-like modifier, while ligase binding is the non-covalent recognition event that positions a substrate or regulator for modification.
Can CRISPR be used to study ubiquitin-like protein ligase binding?
Yes, CRISPR knockout, point-mutation knock-in, tagged knock-in, and overexpression models are widely used to test the function of ligases and their binding partners.
What diseases are linked to ubiquitin-like protein ligase binding?
They include cancer, inflammatory diseases, metabolic disorders, DNA damage syndromes, and age-related macular degeneration.
What is a PROTAC and how does it relate to GO:0044389?
A PROTAC is a chimeric molecule that binds both a target protein and an E3 ligase, using ligase binding to trigger target ubiquitination and degradation.
How does EDITGENE support ubiquitin-like protein ligase binding research?
EDITGENE offers knockout, point-mutation, knock-in, overexpression cell models, CRISPR library screening, and bioinformatics services tailored to ligase-substrate studies.
Conclusion
GO:0044389, ubiquitin-like protein ligase binding, is a fundamental molecular function that determines how ubiquitin and ubiquitin-like modifiers are targeted to specific proteins. It underpins diverse processes including oxygen sensing, inflammasome activation, purinosome assembly, and DNA damage signaling, and it is directly relevant to cancer, inflammation, and degenerative disease. Because ligase binding is a tractable and specific interaction, it is a prime target for functional genomics and therapeutic intervention. CRISPR-based knockout, point-mutation, knock-in, and overexpression models, combined with screening and proteomics, provide a robust toolkit for dissecting these interactions and translating them into new treatments.
References
- 1. Kaarniranta K et al.. 2023. Autophagy in age-related macular degeneration.. Autophagy 19(2):388-400 PMID: 35468037
- 2. Mevissen TET et al.. 2017. Mechanisms of Deubiquitinase Specificity and Regulation.. Annu Rev Biochem 86:159-192 PMID: 28498721
- 3. Sakamoto KM et al.. 2001. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation.. Proc Natl Acad Sci U S A 98(15):8554-9 PMID: 11438690
- 4. Chou MC et al.. 2023. PAICS ubiquitination recruits UBAP2 to trigger phase separation for purinosome assembly.. Mol Cell 83(22):4123-4140.e12 PMID: 37848033
- 5. Qin Y et al.. 2021. TRIM28 SUMOylates and stabilizes NLRP3 to facilitate inflammasome activation.. Nat Commun 12(1):4794 PMID: 34373456
- 6. Dearlove EL et al.. 2024. DTX3L ubiquitin ligase ubiquitinates single-stranded nucleic acids.. Elife 13 PMID: 39377462
- 7. Ivan M et al.. 2001. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.. Science 292(5516):464-8 PMID: 11292862
- 8. Hershko A. 1988. Ubiquitin-mediated protein degradation.. J Biol Chem 263(30):15237-40 PMID: 2844803
